spacer
 
|


OVERVIEW
The advent of tyrosine kinase inhibitor (TKI) therapy that targets the oncogenic BCR-ABL protein has transformed the once fatal chronic myelogenous leukemia (CML) into a manageable chronic malignancy, which requires long-term pharmacological disease management. Monitoring patient response to TKI therapy at recommended time intervals is the cornerstone of patient management and is an important milestone for predicting long-term treatment outcome. The National Comprehensive Cancer Network (NCCN) therapy recommendations for first-line TKIs include first-generation imatinib or second-generation nilotinib or dasatinib. These interactive case studies will review the NCCN guidelines for TKI therapy for treating high- and low-risk patients and will also address the considerations necessary for choosing the best treatment plan, including risk stratification of patients, pregnancy, patients who do not meet their milestones, and if, when, and how to switch therapy.

GOAL
The goal of these case studies is for medical oncologists, hematologists, hematologist/oncologists, and oncology nurses/ advanced practitioners to better understand the current treatment options for patients with CML and how to optimize their use in different patients.

INTENDED AUDIENCE
These case modules are designed medical oncologists, hematologists, hematologist/oncologists, and oncology nurses/advanced practitioners. No prerequisites required.

LEARNING OBJECTIVES
Upon the conclusion of this activity, the participant should be able to:
  • ASSESS the efficacy, safety, and guideline indications for various CML TKI therapy options.
  • EVALUATE cytogenetic and molecular tests as tools to individualize patient management plans.
  • DESCRIBE guideline and evidenced-based data regarding CML therapy adjustments vis-à-vis time-based clinical responses.
DISCLOSURE OF CONFLICTS OF INTEREST
Clinical and Patient Educators Association (CPEA) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices that they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FACULTY
Javier Pinilla-Ibarz, MD, PhD
Associate Member
Director of Immunotherapy
Malignant Hematology Department
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Dr Pinilla-Ibarz reports serving as a consultant/independent contractor and serving on a speakers’ bureau for Bristol-Myers Squibb Company; and reports serving as a consultant/independent contractor for ARIAD Pharmaceuticals, Inc, Bristol-Myers Squibb Company, and Novartis; and serving on a speakers’ bureau for Pfizer Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE/CPE activity:

Name of Planner or Manager
Reported Financial Relationship
Ashley Marostica, RN, MSN Nothing to disclose
Amanda Glazar, PhD Nothing to disclose
Andrea Funk Nothing to disclose
Laura Gilsdorf Nothing to disclose

Mary Gabb, MS, and Melinda Castro (ASiM) report having no relevant financial or advisory relationships with corporate organizations related to this activity.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Clinical and Patient Educators Association (CPEA) and ASiM do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and ASiM. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Clinical and Patient Educators Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPEA Contact Information
For information about the accreditation of this program, please contact CPEA at 303-953-4580 or inquire@cpea-assn.org.

Nursing Continuing Education
Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global-Logo-smThis activity is jointly provided by Global Education Group and ASiM.


Credit Designation
acpe logoGlobal Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-15-184-H04-P)

This is a knowledge based activity.

For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com

Estimated time to complete this activity: 60 minutes.

Release Date: November 23, 2015  Expiration Date: November 23, 2017

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.

SYSTEM REQUIREMENTS
PC: Microsoft Windows 2000 SE or above; Flash Player Plugin (v7.0.1.9 or greater); Internet Explorer (v5.5 or greater), or Firefox; Adobe Acrobat Reader*; MAC: MAC OS 10.2.8; Flash Player Plugin (v7.0.1.9 or greater); Safari; Adobe Acrobat Reader*. *Internet Explorer is not supported on Macintosh systems.

INSTRUCTIONS TO RECEIVE CREDIT
Please complete a brief, unaccredited pre-test before reading this case module. After reading the module, participants may receive credit by completing the CME/CE/CPE test and evaluation online, and receiving a score of 70% or higher. A certificate of participation will be available online immediately following successful completion of the activity.

TABLE OF CONTENTS
Pre-assessment

Case 1: Front-Line Therapy for Chronic-Phase Myeloid Leukemia in a High-Risk Patient
Case 2: Front-Line Therapy in a Low-Risk Patient
Javier Pinilla-Ibarz MD, PhD

Post-assessment

Submit a case to review at meeting:


procced to pretest


spacer  
  spacer
Advanced Studies in Medicine © 2014 Contact Us
spacer  
spacer